Runx2 (Cbfa1/AML3) is a member of the runt family of transcription factors and is a key regulator of bone development that is requisite for the maturation of hypertrophic chondrocytes and osteoblasts (4, 18) . Mutation of the Runx2 gene is associated with human cleidocranial dysplasia (41) . Runx2 null mice die at birth with the absence of a mineralized skeleton (11, 29) . While the requirement of Runx2 for osteoblast differentiation is well documented, Runx2 is also expressed at significant levels in nonosseous tissues, but its function there is unknown. These tissues include the testes (30, 37) , mammary epithelium (25) , thymus (49) , endothelial cells (55) , and transformed cells (9) . Furthermore, elevated Runx2 expression has been reported for breast and prostate tumors and for cancer cell lines that metastasize to the bone environment (6, 62) . Runx2 is associated with growth control, and Runx2-deficient cells show increased proliferation compared to wild-type cells (21, 44) . The family of Runx proteins functions in both cell growth and differentiation. Runx1 is required for hematopoiesis (39, 61) , Runx3 is required for nerve cell development (31) , and mutations of Runx1 and Runx3 are associated with leukemia (39) and gastric cancer (32) , respectively. Thus, the Runx genes, which encode essential transcription factors for organogenesis, are all associated with various types of cancer (8) .
The identification of Runx2 target genes can provide insight into the mechanisms by which Runx2 functions in metastatic cancer cells as well as in normal cellular differentiation. Importantly, the expression of C-terminally deleted Runx2 in vivo disrupted normal skeletal development (11, 17) , and in metastatic breast cancer lines, prevented tumor-mediated osteolysis in the bone environment (5) . Studies have shown that metastatic breast cancer cell lines carrying mutations in the Runx2 protein that inhibit its normal functional activity in subnuclear domains result in blocking of the osteolytic lesions induced by the parental metastatic cell (5, 26) . For this study, we have examined the mechanisms by which Runx2 may contribute to the metastatic properties of cancer cells by identifying novel target genes from a comparison of the expression profiles of genes present in bone tissue from wild-type mice and in tissue from Runx2 ⌬C/⌬C mice, whose Runx2 lacks C-terminal functions and results in embryonic lethality and the absence of a mineralized skeleton (11) .
We have identified a novel Runx2 target gene, the gene for matrix metalloproteinase 9 (MMP9), which is well characterized for its activity during metastasis (13, 19) . The MMPs are a family of extracellular matrix-degrading enzymes that share common functional domains and activation mechanisms. These enzymes are synthesized as secreted transmembrane proenzymes and processed to the active form by removal of an amino-terminal propeptide. The MMPs are endopeptidases that are regulators of cell growth, migration, and extracellular matrix remodeling and are expressed in both bone-forming osteoblasts and bone-resorbing osteoclasts (40) . MMP13 is expressed in osteoblastic cells and has been identified as a Runx2 target gene (23, 43, 52) . MMP9 is highly expressed in monocytes (osteoclast precursors) and in multinucleated osteoclasts that resorb bone (46, 59) . Osteoclasts that resorb calcified cartilage at the growth plate are particularly enriched in MMP9 at the ossification front (58) . Genetic models of MMP13 and MMP9 deficiency exhibit skeletal defects resulting from impaired enzyme activity (40) . Stimulated endothelial cells also express MMP9 in response to cytokines (3) and shear stress (35) during development and after birth. Thus, both MMP9 and Runx2 are expressed in a variety of cell types.
MMPs have long been associated with cancer cell invasion and metastasis (19) . For three decades, MMPs have been projected as potential targets for cancer therapy based on their up-regulation in virtually all human tumors and their ability to degrade all components of the extracellular matrix. The effects of MMP suppression in tumor models were so compelling in preclinical studies that synthetic metalloproteinase inhibitors of enzyme activity were rapidly developed and tested in human clinical trials. The results of these trials, however, have been disappointing (13) . Thus, a better understanding of the regulatory mechanisms that control MMP transcription in cancer cells could provide new avenues for therapeutic intervention that are more specific and effective.
Here we report that MMP9 is a direct target of Runx2 in bone tissue and in metastatic breast and prostate cells. Several lines of evidence are presented to establish a Runx2 regulatory element in the proximal promoter and a definitive role for Runx2 in MMP9-induced expression in cancer cells. We further show that the modulation of Runx2 activity by either forced expression or RNA interference is directly correlated with MMP9 expression and the invasive properties of metastatic cancer cells. Thus, our studies suggest a regulatory linkage between Runx2, the expression of metastatic markers (MMP9 and MMP13), and the invasive behavior of cancer cells.
MATERIALS AND METHODS
Cell culture, transient transfection, and plasmids. Mouse osteoblastic MC3T3-E1 cells and the nonmetastatic MCF-7 and metastatic MDA-MB-231 human breast cancer cell lines were cultured in alpha minimal essential medium (␣-MEM) containing 10% fetal bovine serum (FBS; Invitrogen Inc., CA). Prostate cancer PC3 cells (a gift from L. Chung, University of Virginia, Charlottesville, Virginia) were maintained in T-medium supplemented with 5% FBS. Human cervical carcinoma (HeLa) cells were cultured and maintained in Dulbecco's modified Eagle's medium supplemented with 5% FBS. HeLa or MC3T3 cells were transfected at 50% confluence with 200 ng of promoter reporter and 0.2 to 1.6 g of Runx2 expression plasmid using Superfect reagent (QIAGEN, Valencia, CA). Cells were harvested after 48 h of transfection or viral infection and assayed for luciferase reporter activity. Experiments were performed in triplicate at least three times. A cytomegalovirus promoter-driven Runx2 expression vector and an adenovirus expressing wild-type Runx2 were reported previously (2) . Mouse MMP9 promoter fragments (from Ϫ1.3 kbp to ϩ1 bp and Ϫ250 bp to ϩ1 bp) were PCR amplified from MC3T3 genomic DNA using the forward primers 5Ј-TATCGGGGTACCGAGAGTTTTGTAGAGAG CGTA-3Ј (1.3 kb) and 5Ј-TATCGGGGTACCGTCTGGGGGTCCTGCCTGA CTTGG-3Ј (Ϫ250 bp) and the common reverse primer 5Ј-ATACCGCTCGAG TGGCTAACGCTGCCTTTGCAGA-3Ј, which contains an XhoI site (in italics). PCR products were doubly digested with KpnI and XhoI and cloned upstream of the luciferase gene in the pGL2 vector. A 2-bp substitution mutation (boldface and lowercase) was introduced into the Runx binding element (boldface) using the following primers: 5Ј-TATCGGGGTACCTTTGCAGAAACTAAACCCTG AGTTCTGTacTTTCCTGTG-3Ј for the fragment starting at Ϫ250 bp and 5Ј-ACA AAGTCTGCAGTTTGCAGAAACTAAACCCTGAGTTCTGTacTTTCCTGT G-3Ј for the full-length MMP9 promoter. The incorporation of the mutation was confirmed by automated sequencing. Plasmid constructs containing the mouse MMP9 promoters fused to the luciferase coding sequence were transfected as described previously (27) .
Zymography and Western blot analysis. MMP9 activity was analyzed with gelatin zymograms as described previously (45) . Bone tissue extracts, cell lysates, and culture medium were diluted in 50 mM Tris-HCl, pH 7.4, without reducing agent and separated by electrophoresis in 7.5% sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) containing 2 mg/ml gelatin. After electrophoresis, the gels were washed in 2.5% Triton X-100 for 30 min and then incubated for 16 h at 37°C in 50 mM Tris-HCl, pH 7.4, 200 mM NaCl, 10 mM CaCl 2 . Gels were then stained with Coomassie brilliant blue R-250 and destained with 40% methanol-10% acetic acid until clear bands appeared. Images were captured with an AlphaImager gel documentation system (Alpha Innotech, San Leandro, CA). For Western blot analysis, whole-cell lysates were mixed with Laemmli buffer under reducing conditions and separated by 10% SDS-PAGE as described previously (11) . Proteins were transferred to a polyvinylidene difluoride membrane and incubated with either a 1:200 dilution of rabbit polyclonal MMP9 antibody (Abcam Inc., Cambridge, MA) or a 1:2,000 dilution of mouse monoclonal Runx2 antibody (2), followed by incubation with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz, CA). Immunoreactive proteins were detected using an enhanced chemiluminescence kit (Pierce, Rockford, IL).
Osteogenesis expression array. The total RNA (5 g) isolated from craniofacial skeletons of wild-type or Runx2
⌬C/⌬C embryos (at 17.5 days postcoitum [dpc]) was subjected to a mouse osteogenesis cDNA expression array (SuperArray Bioscience Corporation, Frederick, MD) to examine the expression levels of osteogenic markers according to the manufacturer's protocol.
ChIP. Chromatin immunoprecipitation (ChIP) assays were performed as previously described (22) . Briefly, formaldehyde cross-linking was performed for 10 min in rat osteoblastic cells, and samples were sonicated to obtain DNA fragments with an average size of 0.3 kb. Protein-DNA complexes were immunoprecipitated using Runx2 antibody (M-70; Santa Cruz) or immunoglobulin G (IgG) as a control. DNAs were purified and subjected to PCR amplification. The MMP9 promoter fragment (Ϫ380 to Ϫ130 bp) containing the Runx element was amplified using the forward primer 5Ј-CTCAGAAGCCCAAGGAAGAGT-3Ј and the reverse primer 5Ј-CACTACCCACTCCTTTATGCCC-3Ј. Each PCR was performed using 10% (3 l) of the bound DNA fraction from the chromatin precipitate or 1% (1 l) of the input fraction. The PCR products were separated in 2.0% agarose gels containing 0.5 g/ml ethidium bromide. DNA bands were visualized using UV light and recorded with an AlphaImager gel documentation system. All experiments were repeated at least three times, and representative results are presented in the figures.
Immunostaining. Endogenous MMP9 was detected in bone tissues from wildtype or Runx2 ⌬C/⌬C embryos at 17.5 dpc. Embryos were fixed in paraformaldehyde and embedded in paraffin as described previously (64) . Heads were serially sectioned at 8 m for immunolabeling with a 1:800 dilution of mouse monoclonal MMP9 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature, followed by incubation with a 1:800 dilution of fluorescein isothiocyanate-conjugated secondary antibody (Molecular Probes, Eugene, OR) for 30 min. Sections were further stained with DAPI (4Ј,6Ј-diamidino-2-phenylindole) to stain nuclei, and images were captured with an epifluorescence Axioplan 2 microscope (Zeiss, Inc., Thorwood, NY).
Electrophoretic mobility shift analysis. Nuclear extracts were prepared from osteoblastic ROS 17/2.8 cells or primary rat osteoblasts cultured for 12 and 20 days according to the method of Dignam et al. (15) . Aliquots of supernatant enriched with nuclear proteins were quick-frozen in a dry ice-ethanol bath and stored at Ϫ80°C until further use. The following complementary oligonucleotides representing the wild-type (WT) and mutant (MT) Runx binding elements of the rat MMP9 promoter were synthesized: WT, ACCCTGAGTTCTGTGGTTGTT TCCTGTGGGTCT; and MT, ACCCTGAGTTCTGTacTTTCCTGTGGGTCT (lowercase nucleotides were mutated). The plus strand (10 pmol) was labeled with [␥-
32 P]ATP for 1 h at 37°C with T4 polynucleotide kinase (New England Biolabs, Beverly, MA). The Runx binding cassette was generated by annealing with a threefold excess amount of the minus strand. The unincorporated nucleotides were removed using a quick-spin G-25 Sephadex column (Roche Molecular Biochemicals, Indianapolis, IN). DNA-protein binding reactions were carried out using 10 fmol of radiolabeled probe and 4 to 8 g of nuclear extract at room temperature for 20 min. Protein-DNA complexes were separated in a 6.5% (40:0.5) nondenaturing polyacrylamide-Tris-borate-EDTA gel. For immunoshift analysis, 200 ng of Runx2 antibody was incubated with nuclear extract at 22°C for 30 min prior to the addition of probe. The samples were electrophoresed at 200 V for 3 h at 4°C. Gels were dried and subjected to autoradiography at Ϫ70°C.
siRNA treatment and adenoviral infection. Breast and prostate cancer cells were transfected with small interfering RNA (siRNA) duplexes at 30 to 50% confluence using Oligofectamine (Invitrogen Life Technologies). siRNAs spe- (Stanford, CA). Cells were transfected with either Runx2 or control siRNA duplexes specific for green fluorescent protein (GFP) at concentrations of 25 and 50 nM. For optimal transfection, a reduced serum medium (Opti-MEM) was used to dilute the siRNA duplexes and Oligofectamine per the manufacturer's instructions. After 4 h, the cells were supplemented with ␣-MEM containing 30% FBS for a final concentration of 10% in the medium. The siRNA treatment was carried out for 72 h, after which cells were harvested to isolate total protein and RNA. A knockdown of endogenous Runx2 and its effect on metastatic markers were examined by real-time quantitative PCR (QPCR). For Runx2 overexpression, cells were transduced with an adenovirus (multiplicity of infection [MOI], 10) expressing either Runx2 or a LacZ control for 1.5 h with gentle shaking in medium supplemented with 1% FBS as previously described (2) . Cells were washed twice with serum-free medium after viral infection and cultured in regular medium for another 48 h before being harvested.
Real-time reverse transcription-PCR (RT-PCR) analysis.
The expression levels of MMP2, MMP9, MMP13, and vascular endothelial growth factor (VEGF) in PC3, MCF-7, and MDA-MB-231 cells were analyzed after Runx2 siRNA treatment or adenovirus transduction. Total RNA was isolated using Trizol reagent according to the manufacturer's specifications. RNA was primed with oligo(dT), and cDNAs were synthesized at 42°C with SuperScript II RNA polymerase (Invitrogen). The cDNA was then used for real-time PCR with TaqMan chemistry (Applied Biosystems, Inc., Foster City, CA). Amplicon quantities relative to a standard curve generated from serial dilutions of pooled cDNAs from all samples were determined using ABI Prism software (ABI7900 HT sequence detection system). For PCR amplification, the following primers were used: MMP2 forward, 5Ј-TAGGCCATAGCAGACG-3Ј; MMP2 reverse, 5Ј-TT AAGGCCCATATCAGG-3Ј; MMP9 forward, 5Ј-ATAGACTACTACAGGCT-3Ј; MMP9 reverse, 5Ј-TAGCACGGATAGACCA-3Ј; MMP13 forward, 5Ј-ATG AGCCAGAGTGTCGGTTC-3; MMP13 reverse, 5Ј-GTTAGTAGCGACGAG CAGGAC-3Ј; VEGF forward, 5Ј-AGTTAGTCACACT GGAGATTGAC-3Ј; and VEGF reverse, 5Ј-ATAGGATCGACAGTTGTAACC-3Ј.
Invasion assay. Cells were analyzed for invasion/migration through Matrigel (BD Biosciences) according to the manufacturer's protocol. Briefly, cells were placed in Matrigel inserts or control inserts at 1 ϫ 10 5 cells/ml in serum-free medium and were allowed to migrate for 20 h at 37°C. Nonmigrating cells were removed from the top of the filter by scrubbing with a cotton swab. Cells that migrated were fixed and stained with a Hema 3 kit (Fisher Chemicals). The numbers of cells that migrated to the bottom side of the insert were counted manually and are presented as percentages of invasion.
RESULTS
MMP9 expression is lost in bone tissue of Runx2-deficient mice. To characterize downstream targets and understand the pathways where Runx2 is involved, we performed a limited gene expression profiling analysis using an osteogenic cDNA array (see Materials and Methods) with total RNAs from bone tissue of WT and Runx2 ⌬C/⌬C mice. We identify MMP9 as a novel target of Runx2 (Fig. 1B) . The absence of MMP13, a known target of Runx2 (52), from the expression profile of the Runx2 ⌬C/⌬C mouse validated the hypothesis that the differences observed between the WT and Runx2 mutant bone samples reflect biological consequences. These changes were observed in replicate samples and further confirmed by RT-PCR analysis (Fig. 1B) . The expression of MMP9 was significantly downregulated in Runx2 ⌬C/⌬C mice compared to wild-type littermates. A zymographic analysis of gelatinase activity (Fig.  1C) in total protein extracts from the long bones of wild-type and Runx2
⌬C/⌬C mice showed a significant decrease in pro-MMP9 activity. These results are consistent with the decreased MMP9 protein levels in Runx2 ⌬C/⌬C mice relative to wild-type littermates (Fig. 1D) .
To examine the tissue distribution of MMP9 in bones of WT and Runx2 mutant animals, we performed in situ immunofluorescence analysis using an MMP9 antibody on sections of day 17.5 embryos (Fig. 1E) . The developing exoccipital bone showed abundant MMP9 expression in the growth plate region, where MMP9 has been shown to be maximally expressed (58) , for the WT mice. For the Runx2 mutant mice, MMP9 expression was significantly reduced as confirmed by line scan quantitation of the images. Taken together, these findings implicate MMP9 as a downstream target of Runx2 in bone tissues.
Runx2 mediates induction of MMP9 gene transcription by direct association with the proximal promoter. Four consensus Runx elements are located within 1.3 kb of the 5Ј flanking sequences of the mouse MMP9 gene (Fig. 2A) . Three closely spaced putative sites retain only the CCA motif, while the proximal site is a perfect match to the seven-nucleotide consensus TGTGGTT. We assessed which of these Runx consensus sites may contribute to MMP9 transcription by the transient transfection of osteoblastic MC3T3-E1 cell lines which express endogenous Runx2. Mutation of the proximal Runx binding element resulted in a twofold decrease in the basal activity of the Ϫ1.3-kb and Ϫ250-bp MMP9 promoter deletion fragments (Fig. 2B) . To further show that Runx2 is an activator of MMP9 transcription, the Ϫ1.3-kb or Ϫ250-bp MMP9 promoter reporter construct was cotransfected into HeLa cells, which do not express Runx2, with increasing amounts of a Runx2 expression plasmid. Our results demonstrate a dosedependent increase in the activity of both the Ϫ1.3-kb (Fig. 2C , upper panel) and Ϫ250-bp (middle panel) MMP9 promoter fragments. The Runx site in the MMP9 promoter is also responsive to Runx1, which increases the Ϫ250-bp MMP9 promoter activity to the same extent as Runx2 (Fig. 2C, lower  panel) . Therefore, Runx factors transactivate the MMP9 promoter for regulation of its expression in osseous and nonosseous cells.
To examine the direct association of Runx2 with the MMP9 promoter, we performed in vitro (electrophoretic mobility shift assays) and in vivo (chromatin immunoprecipitation) binding assays (Fig. 3) . Nuclear extracts from rat osteosarcoma (ROS17/2.8) or primary calvarial osteoblasts, a rich source of Runx2 protein, showed a specific protein-DNA interaction (open arrow, Fig. 3A) at the Runx motif in the proximal MMP9 promoter. The presence of Runx2 in this complex was confirmed by a supershift using a polyclonal antibody against Runx2 (filled arrow, Fig. 3A) . The specificity of binding to the putative Runx sites was established by competition analyses with the cold wild-type probe, which completely abolished binding of the complex, while the mutant Runx oligonucleotide failed to compete (Fig. 3B ). A ChIP assay was then performed to examine the in vivo association of Runx2 with the MMP9 gene (Fig. 3C) . Using primary rat osteoblasts, we observed recruitment of Runx2 to the proximal MMP9 promoter. Together, these analyses demonstrate that Runx2 activates transcription of the MMP9 gene by directly binding to a functional Runx2 regulatory element.
Runx2 regulates activity of MMP9 in bone metastatic cancer cells. Matrix metalloproteinases are upregulated in metastatic cancer cells, and MMP9 is a key marker of these cells. We therefore examined whether Runx2 expression is correlated with MMP9 levels in cancer cells. We found MMP9 mRNAs to be highly expressed in breast (MDA-MB-231) and prostate (PC3) cells that metastasize to bone, in contrast to nonmetastatic (MCF-7 and LNCaP) tumor cells (Fig. 4A) . Interestingly, the Runx2 protein was only detected in bone metastatic breast and prostate tumor cells (Fig. 4B) .
These observations provided an opportunity to address the transcriptional regulation of MMP9 by Runx2 in bone metastatic cancer cells. Breast (MDA-MB-231) and prostate (PC3) cancer cells were infected with an adenovirus expressing Runx2 at increasing MOIs and harvested after 48 h of infection (Fig. 5) . The overexpression of Runx2 was confirmed by using a Runx2 monoclonal antibody in Western blot analyses ( Fig.  5A and B, upper panels). We found a dose-dependent increase in endogenous MMP9 mRNA levels as a consequence of Runx2 expression in MDA-MB-231 (Fig. 5A) and PC3 (Fig.   5B ) cells. To further assess whether Runx2 is sufficient to upregulate MMP9 in primary tumor cells also, we infected nonmetastatic breast cancer cells (MCF-7) with increasing MOIs of the Runx2-expressing adenovirus. Figure 5C shows a dose-dependent increase in MMP9 mRNA levels with increasing Runx2 expression levels compared to the case with the control virus. These results demonstrate that Runx2 upregulates endogenous MMP9 expression in bone metastatic cancer cells (Fig. 5A and B) as well as having the capacity to induce MMP9 transcription in nonmetastatic tumor cells (Fig. 5C) . Therefore, Runx2 is a potent activator of the MMP9 gene in cancer cells.
To further document the role of Runx2 in MMP9 transcriptional regulation, we depleted Runx2 in bone metastatic breast 
-QPCR analysis (right panel). Protein extracts from the long bones of WT and Runx2
⌬C/⌬C littermates were resolved by 8% SDS-PAGE with 2% gelatin and processed for zymography (C) and Western blotting (D) as described in Materials and Methods. (E) Immunolocalization of MMP9 in wild-type and Runx2 ⌬C/⌬C mutant embryos (at 17.5 dpc). Embryos were fixed in paraformaldehyde and embedded in paraffin, and the heads were serially sectioned at 8 m. The left panels show MMP9 staining of the growth plate (GP) area of exoccipital bone. The ossification front (OF) is further magnified in the right panels showing the MMP9 signal. (The image was generated by overlaying the MMP9 image with an image that reflects sample autofluorescence. The MMP9 signal is shown in green, the background is shown in red, and autofluorescence is shown in yellow). Quantitation of the MMP9 signal in WT and Runx2 mutant tissue sections is shown by line scanning (the position is indicated in the micrograph) using Metamorph software, which measures the intensity of the fluorescent signal. cancer cells by using RNA interference and measured endogenous levels of MMP9 mRNA and its functional activity by zymography (Fig. 6 ). With increasing amounts (25 nM and 50 nM) of siRNA oligonucleotides for Runx2, Ͼ80% of the Runx2 protein was knocked down, as detected by Western blot analysis (Fig. 6A) . siRNA treatment did not affect cdk2 levels, and the control GFP oligonucleotide did not change the endogenous Runx2 levels. Thus, the RNA interference for Runx2 was specific. The decrease in Runx2 resulted in a more-thanthreefold decrease in MMP9 mRNA, as detected by real-time RT-PCR analysis (Fig. 6B) . We also observe a significant decrease in MMP9 activity in Runx2 siRNA-treated samples compared to GFP-treated or untreated controls (Fig. 6C) . Thus, the inhibition of Runx2 expression results in a downregulation of MMP expression. These results further confirm that MMP9 is significantly regulated by Runx2.
Runx2 influences migration of metastatic cancer cells. MMP9 expression has been implicated in tumor invasion and metastasis. Our results show that Runx2 knockdown decreases MMP9 expression in bone metastatic breast cancer cells (Fig.  6) . Thus, to examine the consequences of Runx2 depletion in metastatic cancer cells on invasive properties, we performed a Matrigel invasion assay with MDA-MB-231 breast cancer cells (Fig. 7) . Cells treated with Runx2 siRNA showed significantly less (16%) invasion than untreated (62%) or GFP control oligonucleotide (47%)-treated cells (Fig. 7A) . In a complementary experiment, we examined the invasion properties of MCF-7 (nonmetastatic) cells overexpressing Runx2 by adenovirus infection (Fig. 7B) 7% in MCF-7 cells) ( Fig. 7A and B, controls) . The overexpression of Runx2 in MCF-7 cells resulted in a threefold increase in the invasion of MCF-7 cells (Fig. 7B ) and was consistent with the increase in MMP9 levels (Fig. 5C) . Thus, these findings indicate that Runx2 can modulate the invasive properties of nonmetastatic cancer cells, in part by increasing MMP9 activity. Because our findings also suggest that Runx2 is linked to the invasive properties of bone metastatic cancer cells, we considered the extent to which the expression of other known Runx2 target genes related to tumorigenic properties is altered in cancer cells.
Several markers of metastasis were examined in MDA-MB-231 breast cancer cells treated with Runx2 siRNA by real-time PCR analysis (Fig. 8A) . We found significant reductions in the mRNA levels of MMP2, MMP13, and VEGF with Runx2 knockdown in comparison to the GFP control oligonucleotide treatment (Fig. 8A) . The expression of ␤-actin did not change with Runx2 siRNA treatment (data not shown). Taken together, these findings suggest that Runx2 plays an important role in cell invasion by affecting the expression of the family of matrix metalloproteinases, as well as that of vascular endothelial growth factor, which was recently characterized as a target of Runx2 in hypertrophic chondrocytes (65) . Figure 8B schematically illustrates the induction of Runx2 target genes expressed by metastatic cells with known functions in the bone environment that may contribute to the osteolysis associated with breast cancer.
DISCUSSION
The family of MMPs, Runx1, and Runx2 are expressed in osteoprogenitors, chondrocytes, and osteoblasts. Our identification of MMP9 as a novel target gene of both Runx1 and Runx2 in osteoblasts supports the concept that Runx factors are important transcriptional regulators of MMP9 and other MMPs for mediating multiple roles of these enzymes during bone formation.
MMP9 is a key inducer of events associated with pathological conditions that include rheumatoid arthritis, tumor invasion, and metastasis. In the present study, we demonstrate by chromatin immunoprecipitation that Runx2 is recruited to the MMP9 promoter and show that Runx2 activates endogenous MMP9 gene expression in normal skeletal, breast, and prostate cancer cells that metastasize to bone. Importantly, Runx2 has been linked to the activities of metastatic cancer cells in the bone microenvironment which result in osteolytic and osteoblastic lesions induced by secreted factors (5, 26, 36, 38, 60) . Our studies show that Runx2 regulates the family of MMPs The mechanism of Runx2-mediated transcriptional regulation of MMP9 should be considered in the context of other factors. Mutation of the Runx2 sites in the MMP9 promoter results in a two-to threefold decrease in transcription. However, other factors (e.g., tumor necrosis factor alpha) stimulate MMP9 transcription through binding to NF-B, AP1, and Sp-1 sites (20, 56, 57, 63) . Among MMP family members, MMP13 activation by parathyroid hormone has been shown to be regulated by interactions of Runx2 with c-Fos and c-Jun at AP-1 sites (14, 23, 43, 52, 53) . Bertrand-Philippe et al. (7) showed that JunD and Runx factors assemble at the adjacent SRE and UTE-1 sites in the TIMP1 promoter and form functional interactions that stimulate transcription. These two examples of genes in cancer cells represent indirect mechanisms of Runx2-mediated activation. Thus, there exists the possibility that Runx2 binding to the MMP9 promoter may lead to a cooperative interaction with other factors, including Ets (16) . Thus, the Runx2 transcriptional effect on MMP9 and other target genes in cancer cells could be amplified through its interaction with other transcription factors in coregulatory complexes.
During osteogenesis, Runx2 functions as a "platform protein" that interacts with a spectrum of coregulatory proteins, including chromatin remodeling factors, to provide combinatorial mechanisms for either inducing or repressing gene transcription. The recruitment of several coregulatory proteins to the MMP9 promoter has been shown to coordinate cell signaling (extracellular signal-regulated kinase and NF-B). Chromatin remodeling by Brg-1, histone modifications, and the sequential recruitment of transcriptional regulators are also critical to the regulation of MMP9 gene expression (34) . We show that the Runx2 binding element in the proximal promoter (Ϫ250), which is necessary for MMP9 gene transcription, is located in a region with neighboring AP-1, NF-B, and Sp-1 sites required for synergistic cooperation on the MMP9 promoter (50) . This complexity of gene transcription involving Runx2 occurs on other gene promoters, including that of the bone-specific osteocalcin gene. Runx2 sites flank the vitamin D response element and are required for chromatin remodeling (28, 42) . Thus, a key feature of Runx regulation is its ability to function in the combinatorial control of gene expression by forming coregulatory interactions at multiple elements and organizing transcriptional complexes in subnuclear domains (33, 54) . Significantly, disruption of the sub- (24) demonstrated that MMP9 is specifically induced in premetastatic lung endothelial cells and macrophages by distant primary tumors via VEGFR-1/Flt-1 tyrosine kinase (TK) and that it promotes lung metastasis. Furthermore, they showed using a genetic approach that the suppression of MMP9 induction by the deletion of either VEGFR-1TK or MMP9 markedly reduced lung metastasis. Cancer cells that metastasize to bone have higher Runx2 levels than primary tumors and also exhibit elevated MMP9 expression and activity. The blocking of MMP9 activity has also been related to a decreased invasion of cancer cells through Matrigel (1) . The knockdown of MMP9 in cells derived from invasive and metastatic Ewing's sarcoma inhibits migration toward fibronectin (48) , suggesting that depleting key markers for metastasis decreases invasion. Here we show that a Runx2 knockdown by RNA interference in bone metastatic cancer cells downregulates MMP9 and reduces cell migration.
The upregulation of Runx2 expression in breast (6, 51) and prostate (10) cancer cells suggests an important functional contribution of Runx2 in tumorigenic cells. Our siRNA studies also indicate a role for Runx2 in regulating the invasion of bone metastatic cancer cells (MDA-MB-231 cells), in part through the transcriptional regulation of MMP9, but also through other Runx target genes, such as VEGF. Notably, VEGF is a primary component of tumor formation and metastasis (12) . The VEGF gene is a characterized target of Runx2, and it has been shown that Runx2 is a necessary component of a tissue-specific genetic program that regulates VEGF for the progression of endochondral bone formation (65) . Runx2 controls osteoblast differentiation from mesodermal cell populations by regulating bone-specific genes that include osteocalcin, bone sialoprotein (BSP), VEGF, MMP13, Fig. 8B ). These genes are associated with various tumors; for example, human malignant melanoma cells express BSP in relation to Runx2 in vivo as a function of the extent of local invasion (47) . Because Runx2 regulates the expression of key markers implicated in tumor invasion and metastasis (VEGF, BSP, and matrix metalloproteinases [collagenase 3, membrane type 1 matrix metalloproteinase, and MMP9]), the presence of Runx2 appears to be an earlier upstream event in the further activation of tumor-related genes in the bone microenvironment (Fig. 8B) . The perturbation of Runx2 regulatory function in breast cancer cells has been shown to abolish the cellular activity that causes osteolytic lesions in vivo in the bone environment (5, 26) . The present study provides insight into mechanisms that include the direct control of cell invasion and the expression of metastasis-related factors by Runx2. Other studies are required to definitively establish that Runx2 mediates the metastasis of cells from a primary tumor to secondary sites. 
